ClinicalTrials.gg
CompletedNCT03078478CONCLUDEUpdated Jan 11, 2022Results posted

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

A Phase 3 interventional study of Insulin degludec and Insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 229 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,609
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
3rd of 70
1,609 · median 384
Started
2017
with 4 others
Phase 3
49 of 70
2 open now
Registered
52nd of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 5 that started in 2017, is one of 49 in phase 3, and was the 52nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe and North America. The aim of the trial is to compare the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs. Due to change in glycaemic data collection process, this trial is amended to allow for a full 36 weeks (maintenance 2 period) of the use of the new process.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 1,609 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria: - Male or female, age above or equal to 18 years at the time of signing . - Subjects fulfilling at least one of the below criteria (For this inclusion criterion the aim is to include minimum 80% of individuals with a previous episode of hypoglycaemia (criterion e). The remaining subjects will have to fulfil at least one of criteria a-d.): - a) Experienced at least one severe hypoglycaemic episode within the last year (according to the ADA definition, April 2013 (An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.). - b) Moderate chronic renal failure, defined as 30 - 59 mL/min/1.73 m\^2 per CKD-EPI by central laboratory analysis. - c) Hypoglycaemic symptom unawareness (History of impaired autonomic responses (tremulousness, sweating, palpitations, and hunger) during hypoglycaemia). - d) Treated with insulin for more than 5 years. - e) Episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (equal to or below 70 mg/dL [equal to or below 3.9 mmol/L])) within the last 12 weeks prior to Visit 1 (screening). - Subjects diagnosed (clinically) with type 2 diabetes mellitus. - Treated with basal only insulin (once daily or twice-daily insulin (insulin detemir; insulin glargine 100 U/mL, biosimilar of insulin glargine 100 U/mL or insulin Neutral Protamine Hagedorn)) equal to or above 90 days prior to the day of screening with or without any of the following anti-diabetic drugs with stable doses for equal to or above 90 days prior to screening: - a) Metformin - b) Dipeptidyl peptidase -4 inhibitor - c) Sodium-glucose co-transporter 2 inhibitor - d) Alpha-glucosidase-inhibitors (acarbose) - e) Thiazolidinediones - f) Marketed oral combination products only including the products listed in criteria 5a-5e - equal to or below 9.5% (80 mmol/mol) at screening by central laboratory analysis. - equal to or below 45 kg/m\^2. Exclusion Criteria: - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,609 participants (actual)

Study arms

  • Experimental
    IDeg 200 U/mL

    Drug: Insulin degludec

  • Active comparator
    IGlar 300 U/mL

    Drug: Insulin glargine

Interventions

  • For subcutaneous (s.c., under the skin) injection once daily

  • For subcutaneous (s.c., under the skin) injection once daily

07

What researchers measure

Primary outcomes

  1. Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)

    Severe or BG confirmed symptomatic hypoglycaemia was evaluated during maintenance 2 (36 weeks) period. Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

    Time frame: 36 Weeks

Secondary outcomes

  1. Basal Insulin Dose (U) at End of Treatment (up to 88 Weeks)

    The observed mean daily basal insulin doses was evaluated at the end of trial (88 weeks).

    Time frame: 88 weeks

  2. Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)

    Nocturnal severe or BG confirmed symptomatic hypoglycaemia was evaluated during maintenance 2 (36 weeks). The nocturnal period defined as the period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

    Time frame: 36 weeks

  3. Number of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)

    Severe hypoglycaemia are those episodes positively adjudicated by the event adjudication committee according to the ADA definition of a severe hypoglycaemic episode. This was evaluated for maintenance 2 period. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

    Time frame: 36 weeks (maintenance 2)

  4. Change in HbA1c From Baseline to End of Treatment (up to 88 Weeks)

    Change in glycosylated haemoglobin (HbA1c) was evaluated from baseline to end of treatment period (week 88).

    Time frame: Week 0, week 88

  5. Change in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks)

    Change in fasting plasma glucose (FPG) was evaluated from baseline to end of treatment period (week 88).

    Time frame: Week 0, week 88

  6. Percentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)

    Participants achieving a fasting plasma glucose value of less than or equal to 7.2 mmol/L (130 mg/dL) at end of treatment (up to 88 weeks).

    Time frame: At 88 weeks

  7. Percentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)

    Participants achieving a fasting plasma glucose value of less than or equal to 5.0 mmol/L (90 mg/dL) at end of treatment (up to 88 weeks).

    Time frame: At 88 weeks

  8. Percentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)

    Participants achieving target HbA1c of less than 7.0% at the end of treatment (88 weeks) without severe or BG-confirmed hypoglycaemia during maintenance 2 (36 weeks).

    Time frame: End of Treatment (up to 88 Weeks)

  9. Percentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)

    Participants achieving target HbA1c of less than 7.0% at the end of treatment (88 weeks) without nocturnal severe or BG-confirmed hypoglycaemia during maintenance 2 (36 weeks).

    Time frame: At 88 weeks

  10. Change in Mean Pre-breakfast Self-measured Plasma Glucose Used for Titration From Baseline to End of Treatment (up to 88 Weeks)

    Participants measured their pre-breakfast self-measured plasma glucose (SMPG) value until end of treatment (week 88). Mean pre-breakfast self-measured plasma glucose used for titration at baseline and end of treatment (up to 88 weeks) are presented.

    Time frame: Week 0, week 88

  11. Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)

    Severe or BG confirmed symptomatic hypoglycaemia was evaluated during treatment (up to 88 weeks). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

    Time frame: 88 weeks

  12. Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)

    Nocturnal severe or BG confirmed symptomatic hypoglycaemia was evaluated at the end of trial (88 weeks). The nocturnal period defined as the period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

    Time frame: 88 weeks

  13. Number of Severe Hypoglycaemic Episodes During Treatment (up to 88 Weeks)

    Severe hypoglycaemia are those episodes positively adjudicated by the event adjudication committee according to the ADA definition of a severe hypoglycaemic episode. This was evaluated for the total trial period (88 weeks). The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

    Time frame: 88 weeks

  14. Number of Adverse Events From Randomisation to End of Maintenance Period 2 (up to 88 Weeks)

    The adverse events presented are treatment emergent. A treatment-emergent AE (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last days of randomised treatment or had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last date of randomised treatment. Number of adverse events expressed in rates, from randomisation to end of maintenance period 2 (up to 88 weeks) is presented. Rate = number of events divided by patient years of exposure multiplied by 100.

    Time frame: 88 weeks

  15. Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks)

    Change in body weight, measured in kilograms, from baseline (week 0) to end of treatment (week 88).

    Time frame: Week 0, week 88

08

Results

Posted Mar 12, 2020

Participant flow

The trial was conducted at 230 sites in 11 countries as follows. Number of sites that screened and randomised participants to treatment are given in parenthesis. Canada:(9/9), Denmark: (6/6), Estonia: (5/5), Germany: (11 /11), Greece: (7/7), Hungary: (9/9), Norway: (4/4), Poland: (9/9), Romania: (5/4), Serbia: (8/8), United States: (157/153).

Titration Period (16 Weeks)
Participant flow — Titration Period (16 Weeks)
MilestoneInsulin Degludec U200Insulin Glargine U300
Started805804
Full analysis set805804
Safety analysis set802798
Completed805804
Not completed00
Maintenance Period 1 (36 Weeks)
Participant flow — Maintenance Period 1 (36 Weeks)
MilestoneInsulin Degludec U200Insulin Glargine U300
Started805804
Completed758761
Not completed4743
Withdrew: Withdrawal by subject3636
Withdrew: Lost to follow-up74
Withdrew: Death33
Withdrew: Subject withdrawal reason not collected10
Maintencance Period 2 (36 Weeks)
Participant flow — Maintencance Period 2 (36 Weeks)
MilestoneInsulin Degludec U200Insulin Glargine U300
Started758761
Completed733734
Not completed2527
Withdrew: Withdrawal by subject1813
Withdrew: Lost to follow-up36
Withdrew: Death46
Withdrew: Not reconsenting02

Outcome measures

PrimaryNumber of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)

Severe or BG confirmed symptomatic hypoglycaemia was evaluated during maintenance 2 (36 weeks) period. Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

Time frame:
36 Weeks
Reported as:
Number · Episodes/(PYE*100)
Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
Episodes/(PYE*100)Insulin Degludec 200Insulin Glargine U300
Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)216.8243.9
Statistical analysis
  • Insulin Degludec 200 vs Insulin Glargine U300 · Regression, Cox · p = 0.1715 · Treatment rate ratio: 0.88 · 95% CI 0.73 to 1.06
SecondaryBasal Insulin Dose (U) at End of Treatment (up to 88 Weeks)

The observed mean daily basal insulin doses was evaluated at the end of trial (88 weeks).

Time frame:
88 weeks
Reported as:
Mean · Units
Basal Insulin Dose (U) at End of Treatment (up to 88 Weeks)
UnitsInsulin Degludec 200Insulin Glargine U300
Basal Insulin Dose (U) at End of Treatment (up to 88 Weeks)66.6 ± 48.5473.0 ± 48.48
SecondaryNumber of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)

Nocturnal severe or BG confirmed symptomatic hypoglycaemia was evaluated during maintenance 2 (36 weeks). The nocturnal period defined as the period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

Time frame:
36 weeks
Reported as:
Number · Episodes/(PYE*100)
Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
Episodes/(PYE*100)Insulin Degludec 200Insulin Glargine U300
Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)62.3093.75
SecondaryNumber of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)

Severe hypoglycaemia are those episodes positively adjudicated by the event adjudication committee according to the ADA definition of a severe hypoglycaemic episode. This was evaluated for maintenance 2 period. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

Time frame:
36 weeks (maintenance 2)
Reported as:
Number · Episodes/(PYE*100)
Number of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
Episodes/(PYE*100)Insulin Degludec 200Insulin Glargine U300
Number of Severe Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)0.984.88
SecondaryChange in HbA1c From Baseline to End of Treatment (up to 88 Weeks)

Change in glycosylated haemoglobin (HbA1c) was evaluated from baseline to end of treatment period (week 88).

Time frame:
Week 0, week 88
Reported as:
Mean · Percentage of HbA1c
Change in HbA1c From Baseline to End of Treatment (up to 88 Weeks)
Percentage of HbA1cInsulin Degludec 200Insulin Glargine U300
Change in HbA1c From Baseline to End of Treatment (up to 88 Weeks)-0.54 ± 0.91-0.46 ± 0.90
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks)

Change in fasting plasma glucose (FPG) was evaluated from baseline to end of treatment period (week 88).

Time frame:
Week 0, week 88
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks)
mg/dLInsulin Degludec 200Insulin Glargine U300
Change in Fasting Plasma Glucose (FPG) From Baseline to End of Treatment (up to 88 Weeks)-35.50 ± 49.34-25.68 ± 56.69
SecondaryPercentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)

Participants achieving a fasting plasma glucose value of less than or equal to 7.2 mmol/L (130 mg/dL) at end of treatment (up to 88 weeks).

Time frame:
At 88 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With FPG ≤ 7.2 mmol/L (130 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)
Percentage of participantsInsulin Degludec 200Insulin Glargine U300
Yes84.072.0
No16.028.0
SecondaryPercentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)

Participants achieving a fasting plasma glucose value of less than or equal to 5.0 mmol/L (90 mg/dL) at end of treatment (up to 88 weeks).

Time frame:
At 88 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With FPG ≤ 5.0 mmol/L (90 mg/dL) at End of Treatment (up to 88 Weeks) (Yes/no)
Percentage of participantsInsulin Degludec 200Insulin Glargine U300
Yes31.521.7
No68.578.3
SecondaryPercentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)

Participants achieving target HbA1c of less than 7.0% at the end of treatment (88 weeks) without severe or BG-confirmed hypoglycaemia during maintenance 2 (36 weeks).

Time frame:
End of Treatment (up to 88 Weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)
Percentage of participantsInsulin Degludec 200Insulin Glargine U300
Yes35.330.0
No64.770.0
SecondaryPercentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)

Participants achieving target HbA1c of less than 7.0% at the end of treatment (88 weeks) without nocturnal severe or BG-confirmed hypoglycaemia during maintenance 2 (36 weeks).

Time frame:
At 88 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c < 7.0% (53 mmol/Mol) at End of Treatment (up to 88 Weeks) and no Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) (Yes/no)
Percentage of participantsInsulin Degludec 200Insulin Glargine U300
Yes47.439.3
No52.660.7
SecondaryChange in Mean Pre-breakfast Self-measured Plasma Glucose Used for Titration From Baseline to End of Treatment (up to 88 Weeks)

Participants measured their pre-breakfast self-measured plasma glucose (SMPG) value until end of treatment (week 88). Mean pre-breakfast self-measured plasma glucose used for titration at baseline and end of treatment (up to 88 weeks) are presented.

Time frame:
Week 0, week 88
Reported as:
Mean · mmol/L
Change in Mean Pre-breakfast Self-measured Plasma Glucose Used for Titration From Baseline to End of Treatment (up to 88 Weeks)
mmol/LInsulin Degludec 200Insulin Glargine U300
Baseline (week 0)8.39 ± 2.738.41 ± 2.75
End of treatment (week 88)5.46 ± 1.085.56 ± 1.23
SecondaryNumber of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)

Severe or BG confirmed symptomatic hypoglycaemia was evaluated during treatment (up to 88 weeks). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

Time frame:
88 weeks
Reported as:
Number · Episodes/(PYE*100)
Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
Episodes/(PYE*100)Insulin Degludec 200Insulin Glargine U300
Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)137.8163.7
SecondaryNumber of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)

Nocturnal severe or BG confirmed symptomatic hypoglycaemia was evaluated at the end of trial (88 weeks). The nocturnal period defined as the period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemia: An episode that is severe according to the ADA 2013 classification or blood glucose (BG) confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe or BG-confirmed symptomatic hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

Time frame:
88 weeks
Reported as:
Number · Episodes/(PYE*100)
Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
Episodes/(PYE*100)Insulin Degludec 200Insulin Glargine U300
Number of Nocturnal, Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Treatment (up to 88 Weeks)36.9360.03
SecondaryNumber of Severe Hypoglycaemic Episodes During Treatment (up to 88 Weeks)

Severe hypoglycaemia are those episodes positively adjudicated by the event adjudication committee according to the ADA definition of a severe hypoglycaemic episode. This was evaluated for the total trial period (88 weeks). The observed rates (number of episodes divided by patient years of exposure multiplied by 100) of severe hypoglycaemic episodes per patient years of exposure (PYE) is presented in this endpoint results.

Time frame:
88 weeks
Reported as:
Number · Episodes/(PYE*100)
Number of Severe Hypoglycaemic Episodes During Treatment (up to 88 Weeks)
Episodes/(PYE*100)Insulin Degludec 200Insulin Glargine U300
Number of Severe Hypoglycaemic Episodes During Treatment (up to 88 Weeks)2.065.21
SecondaryNumber of Adverse Events From Randomisation to End of Maintenance Period 2 (up to 88 Weeks)

The adverse events presented are treatment emergent. A treatment-emergent AE (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last days of randomised treatment or had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last date of randomised treatment. Number of adverse events expressed in rates, from randomisation to end of maintenance period 2 (up to 88 weeks) is presented. Rate = number of events divided by patient years of exposure multiplied by 100.

Time frame:
88 weeks
Reported as:
Number · Episodes/(PYE*100)
Number of Adverse Events From Randomisation to End of Maintenance Period 2 (up to 88 Weeks)
Episodes/(PYE*100)Insulin Degludec 200Insulin Glargine U300
Number of Adverse Events From Randomisation to End of Maintenance Period 2 (up to 88 Weeks)367.32365.42
SecondaryChange in Body Weight From Baseline to End of Treatment (up to 88 Weeks)

Change in body weight, measured in kilograms, from baseline (week 0) to end of treatment (week 88).

Time frame:
Week 0, week 88
Reported as:
Mean · kg
Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks)
kgInsulin Degludec 200Insulin Glargine U300
Change in Body Weight From Baseline to End of Treatment (up to 88 Weeks)2.9 ± 5.171.7 ± 5.84

Adverse events

Collected over From the first trial-related activity after the subject had signed the informed consent until the End of Trial (week 88) + 7 days follow-up period. Results are based on the safety analysis set (SAS), which comprised all participants who received at least one dose of trial product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg U2007/802 (0.9%)167/802 (20.8%)496/802 (61.8%)
IGlar U3009/798 (1.1%)141/798 (17.7%)476/798 (59.6%)
Most frequent serious events
Showing 10 of 309
Most frequent serious events
EventIDeg U200IGlar U300
HypoglycaemiaMetabolism and nutrition disorders8/80219/798
Coronary artery diseaseCardiac disorders10/8025/798
Hypoglycaemic unconsciousnessNervous system disorders3/8029/798
PneumoniaInfections and infestations6/8029/798
Atrial fibrillationCardiac disorders9/8025/798
Acute kidney injuryRenal and urinary disorders4/8028/798
Acute myocardial infarctionCardiac disorders6/8022/798
Angina unstableCardiac disorders6/8024/798
Cardiac failure congestiveCardiac disorders6/8023/798
OsteoarthritisMusculoskeletal and connective tissue disorders2/8025/798
Most frequent other events
Showing 10 of 14
Most frequent other events
EventIDeg U200IGlar U300
NasopharyngitisInfections and infestations152/802161/798
Upper respiratory tract infectionInfections and infestations145/802122/798
DiarrhoeaGastrointestinal disorders72/80279/798
ArthralgiaMusculoskeletal and connective tissue disorders51/80265/798
Back painMusculoskeletal and connective tissue disorders59/80262/798
HeadacheNervous system disorders51/80262/798
InfluenzaInfections and infestations59/80241/798
NauseaGastrointestinal disorders43/80250/798
Urinary tract infectionInfections and infestations49/80247/798
BronchitisInfections and infestations48/80246/798

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Insulin Degludec U200Insulin Glargine U300Total
Mean62.9 ± 1062.8 ± 1062.8 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec U200Insulin Glargine U300Total
Female333368701
Male472436908
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin Degludec U200Insulin Glargine U300Total
Hispanic or Latino84100184
Not Hispanic or Latino7217041425
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Degludec U200Insulin Glargine U300Total
American Indian or Alaska Native549
Asian252954
Native Hawaiian or Other Pacific Islander011
Black or African American7865143
White6936991392
More than one race000
Unknown or Not Reported4610
09

Study locations

229 sites
  • Novo Nordisk Investigational Site
    Anniston, Alabama 36207, United States
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35211, United States
  • Novo Nordisk Investigational Site
    Chandler, Arizona 85224, United States
  • Novo Nordisk Investigational Site
    Fountain Hills, Arizona 85268, United States
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85306-4652, United States
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85306, United States
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85308, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85037, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85741, United States
  • Novo Nordisk Investigational Site
    Buena Park, California 90620, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Downey, California 90242, United States
  • Novo Nordisk Investigational Site
    Duarte, California 91010, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Lomita, California 90717, United States
  • Novo Nordisk Investigational Site
    Los Alamitos, California 90720, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Moreno Valley, California 92555, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Palm Springs, California 92262, United States
  • Novo Nordisk Investigational Site
    Pomona, California 91766-2007, United States
  • Novo Nordisk Investigational Site
    Poway, California 92064, United States
  • Novo Nordisk Investigational Site
    Riverside, California 92506, United States
  • Novo Nordisk Investigational Site
    Roseville, California 95661, United States
  • Novo Nordisk Investigational Site
    Sacramento, California 95821, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Stanford, California 94305, United States
  • Novo Nordisk Investigational Site
    Vista, California 92083, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    West Hills, California 91304, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80918, United States
  • Novo Nordisk Investigational Site
    Englewood, Colorado 80113, United States
  • Novo Nordisk Investigational Site
    Waterbury, Connecticut 06708, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Brandon, Florida 33511, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33765, United States
  • Novo Nordisk Investigational Site
    Cooper City, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32258, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32277, United States
  • Novo Nordisk Investigational Site
    Miami Springs, Florida 33166, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33175, United States
  • Novo Nordisk Investigational Site
    New Port Richey, Florida 34652, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32825, United States
  • Novo Nordisk Investigational Site
    Ormond Beach, Florida 32174, United States
  • Novo Nordisk Investigational Site
    Palm Harbor, Florida 34684-3609, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33027, United States
  • Novo Nordisk Investigational Site
    Port Charlotte, Florida 33952, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33606, United States
  • Novo Nordisk Investigational Site
    Marietta, Georgia 30067, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96814, United States
  • Novo Nordisk Investigational Site
    Blackfoot, Idaho 83221, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    Peoria, Illinois 61603, United States
  • Novo Nordisk Investigational Site
    Skokie, Illinois 60077, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62711, United States
  • Novo Nordisk Investigational Site
    Wauconda, Illinois 60084, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47713, United States
  • Novo Nordisk Investigational Site
    Mishawaka, Indiana 46544, United States
  • Novo Nordisk Investigational Site
    Valparaiso, Indiana 46383, United States
  • Novo Nordisk Investigational Site
    Council Bluffs, Iowa 51501, United States
  • Novo Nordisk Investigational Site
    West Des Moines, Iowa 50265, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40502, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40213, United States
  • Novo Nordisk Investigational Site
    Paducah, Kentucky 42001, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70119, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Bloomfield Hills, Michigan 48302, United States
  • Novo Nordisk Investigational Site
    Richfield, Minnesota 55432, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    Kalispell, Montana 59901, United States
  • Novo Nordisk Investigational Site
    Elkhorn, Nebraska 68022, United States
  • Novo Nordisk Investigational Site
    Fremont, Nebraska 68025, United States
  • Novo Nordisk Investigational Site
    Omaha, Nebraska 68144, United States
  • Novo Nordisk Investigational Site
    Henderson, Nevada 89052, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89109, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89118, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89148, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    East Brunswick, New Jersey 08816, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87109-2134, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12203, United States
  • Novo Nordisk Investigational Site
    New Windsor, New York 12553, United States
  • Novo Nordisk Investigational Site
    New York, New York 10016, United States
  • Novo Nordisk Investigational Site
    Northport, New York 11768, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28210, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28277, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27858, United States
  • Novo Nordisk Investigational Site
    Morehead City, North Carolina 28557-4346, United States

Showing the first 100 of 229 sites across 12 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Philis-Tsimikas A, Stratton I, Norgard Troelsen L, Anker Bak B, Leiter LA. Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478). J Diabetes Sci Technol. 2019 May;13(3):498-506. doi: 10.1177/1932296819841585. Epub 2019 Apr 11. PubMed 30974986 ↗
  • Philis-Tsimikas A, Klonoff DC, Khunti K, Bajaj HS, Leiter LA, Hansen MV, Troelsen LN, Ladelund S, Heller S, Pieber TR; CONCLUDE Study Group. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia. 2020 Apr;63(4):698-710. doi: 10.1007/s00125-019-05080-9. Epub 2020 Jan 27. PubMed 31984443 ↗
  • Evans M, Moes RGJ, Pedersen KS, Gundgaard J, Pieber TR. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial. Adv Ther. 2020 May;37(5):2413-2426. doi: 10.1007/s12325-020-01332-y. Epub 2020 Apr 18. PubMed 32306247 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Feb 2019, 23 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2017
First posted
Mar 13, 2017
StartActual
Mar 13, 2017
Primary completionActual
Feb 13, 2019
CompletionActual
Mar 4, 2019
Results first posted
Mar 12, 2020
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03078478
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 13, 2017
Start date
Mar 13, 2017
Primary completion
Feb 13, 2019
Completion
Mar 4, 2019
Results posted
Mar 12, 2020
Last update
Jan 11, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion